Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech can feel like decoding lab notes. Dyne Therapeutics’ SEC filings stretch across technical 10-Ks, rapid-fire 8-Ks on trial milestones, and daily Form 4 insider trades. Finding cash-runway details or deciphering collaboration clauses shouldn’t slow your research.
Stock Titan solves this problem. Our AI reads every Dyne Therapeutics document the moment it hits EDGAR, then delivers plain-English briefs so you can instantly answer questions such as “understanding Dyne Therapeutics SEC documents with AI” or “Dyne Therapeutics insider trading Form 4 transactions.” Whether you need the latest Dyne Therapeutics quarterly earnings report 10-Q filing or a Dyne Therapeutics 8-K material events explained, the platform keeps you current.
- 10-K Annual Report – Cash runway, R&D spend, and FORCE platform risks, with Dyne Therapeutics annual report 10-K simplified for quick review.
- 10-Q Quarterly Update – Revenue, expenses, and trial progress in a Dyne Therapeutics earnings report filing analysis.
- 8-K Material Events – Real-time alerts on clinical data releases and financing rounds.
- Form 4 – Dyne Therapeutics Form 4 insider transactions real-time so you can track executive stock transactions before the market reacts.
- DEF 14A Proxy – Dyne Therapeutics proxy statement executive compensation distilled into clear metrics.
Every filing includes AI-powered summaries, keyword search, and side-by-side comparisons so you can monitor trial timelines, segment expenses, and “Dyne Therapeutics SEC filings explained simply” without wading through hundreds of pages.
Dyne Therapeutics reported a Form 144 notice showing a proposed sale of 4,552 shares of Common Stock on 09/04/2025 through Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $60,402. The shares were acquired as Restricted Stock Units from the issuer on 09/03/2025 (11,875 units) and 09/04/2025 (3,000 units), with payment noted as cash. The filer also disclosed a prior sale of 1,342 shares on 06/05/2025 yielding $17,911. The notice includes the seller's representation that no undisclosed material adverse information is known.
Dyne Therapeutics (Nasdaq: DYN) filed an 8-K stating that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antisense oligonucleotide DYNE-251 for Duchenne muscular dystrophy patients amenable to exon 51 skipping. BTD provides earlier, more frequent FDA interactions and eligibility for priority review, potentially shortening time to market if efficacy and safety are confirmed. The filing furnishes, but does not file, the related press release as Exhibit 99.1 and contains no financial statements, trial data, or updated guidance. Management characterizes the event as material under Regulation FD, signaling strategic importance to Dyne’s pipeline and future revenue prospects, but investors must note that DYNE-251 still requires successful pivotal studies and eventual FDA approval.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
